BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 1403060)

  • 1. Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study.
    de Forni M; Malet-Martino MC; Jaillais P; Shubinski RE; Bachaud JM; Lemaire L; Canal P; Chevreau C; Carrié D; Soulié P
    J Clin Oncol; 1992 Nov; 10(11):1795-801. PubMed ID: 1403060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cardiotoxicity of continuous intravenous infusion of 5-fluorouracil: clinical study, prevention and physiopathology. Apropos of 13 cases].
    de Forni M; Bugat R; Sorbette F; Delay M; Bachaud JM; Chevreau C
    Bull Cancer; 1990; 77(5):429-38. PubMed ID: 2205312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study.
    Kosmas C; Kallistratos MS; Kopterides P; Syrios J; Skopelitis H; Mylonakis N; Karabelis A; Tsavaris N
    J Cancer Res Clin Oncol; 2008 Jan; 134(1):75-82. PubMed ID: 17636329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiotoxicity of 5-fluorouracil in 1350 patients with no prior history of heart disease.
    Tsibiribi P; Descotes J; Lombard-Bohas C; Barel C; Bui-Xuan B; Belkhiria M; Tabib A; Timour Q
    Bull Cancer; 2006 Mar; 93(3):E27-30. PubMed ID: 16567310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I and pharmacokinetic study of docetaxel administered in combination with continuous intravenous infusion of 5-fluorouracil in patients with advanced solid tumors.
    Van Den Neste E; de Valeriola D; Kerger J; Bleiberg H; Kusenda Z; Brassinne C; Bartholomeus S; Selleslags J; Hennebert P; Wythouck H; Cazenave I; Lefresne-Soulas F; Piccart M
    Clin Cancer Res; 2000 Jan; 6(1):64-71. PubMed ID: 10656433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors.
    Saltz LB; Kanowitz J; Kemeny NE; Schaaf L; Spriggs D; Staton BA; Berkery R; Steger C; Eng M; Dietz A; Locker P; Kelsen DP
    J Clin Oncol; 1996 Nov; 14(11):2959-67. PubMed ID: 8918493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of refractory metastatic breast cancer with 5-fluorouracil and levofolinic acid as 48 hours continuous venous infusion.
    Gebbia V; Mauceri G; Testa A; Tirrito M; Varvara F; Cucchiara A; Borsellino N; Girlando A; Ferrara M; Caruso F
    Anticancer Res; 1999; 19(3B):2289-92. PubMed ID: 10472346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer.
    Schöber C; Papageorgiou E; Harstrick A; Bokemeyer C; Mügge A; Stahl M; Wilke H; Poliwoda H; Hiddemann W; Köhne-Wömpner CH
    Cancer; 1993 Oct; 72(7):2242-7. PubMed ID: 8374883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5-Fluorouracil, high-dose folinic acid and mitomycin C combination chemotherapy in previously treated patients with advanced colorectal carcinoma.
    Seitz JF; Perrier H; Giovannini M; Capodano G; Bernardini D; Bardou VJ
    J Chemother; 1998 Jun; 10(3):258-65. PubMed ID: 9669654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Symptomatic cardiotoxicity with high-dose 5-fluorouracil infusion: a prospective study.
    Akhtar SS; Salim KP; Bano ZA
    Oncology; 1993; 50(6):441-4. PubMed ID: 8233284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5-fluorouracil cardiotoxicity is a rare, dose and schedule-dependent adverse event: a prospective study.
    Tsavaris N; Kosmas C; Vadiaka M; Skopelitis E; Kopteridis P; Pamouki S; Efremidis M; Kasparian H; Moisakis I; Sakelariou D; Koufos C
    J BUON; 2005; 10(2):205-11. PubMed ID: 17343330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of refractory metastatic breast cancer with 5-fluorouracil plus levofolinic acid as continuous venous infusion: a phase II study.
    Gebbia V; Borsellino N; Testa A; Tirrito M; Varvara F; Cucchiara A; Mauceri G; Girlando A; Ferrara M; Caruso F
    Anticancer Res; 1999; 19(4C):3553-7. PubMed ID: 10629652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Symptomatic cardiotoxicity associated with 5-fluorouracil.
    Meyer CC; Calis KA; Burke LB; Walawander CA; Grasela TH
    Pharmacotherapy; 1997; 17(4):729-36. PubMed ID: 9250550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas.
    Fety R; Rolland F; Barberi-Heyob M; Hardouin A; Campion L; Conroy T; Merlin JL; Rivière A; Perrocheau G; Etienne MC; Milano G
    Clin Cancer Res; 1998 Sep; 4(9):2039-45. PubMed ID: 9748117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiotoxicity following different doses and schedules of 5-fluorouracil administration for malignancy -- a survey of 427 patients.
    Tsavaris N; Kosmas C; Vadiaka M; Efremidis M; Zinelis A; Beldecos D; Sakelariou D; Koufos C; Stamatelos G
    Med Sci Monit; 2002 Jun; 8(6):PI51-7. PubMed ID: 12070449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cardiotoxicity of 5-fluorouracil: report of 6 cases].
    Timour Q; Lombard-Bohas C; Slim R; Barel C; Bui-Xuan B; Tabib A; Bricca G; Malonne H; Vial T; Iordescu D; Descotes J
    Therapie; 2002; 57(3):302-6. PubMed ID: 12422546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Acute cardiac toxicity of 5-fluorouracil: pharmacokinetic correlation].
    Gamelin E; Gamelin L; Larra F; Turcant A; Alain P; Maillart P; Allain YM; Minier JF; Dubin J
    Bull Cancer; 1991; 78(12):1147-53. PubMed ID: 1786427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative cardiac toxicity in two treatment schedules of 5-FU/LV for colorectal carcinoma.
    Najam R; Bano N; Mateen A
    Pak J Pharm Sci; 2013 Sep; 26(5):1013-22. PubMed ID: 24035961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer.
    Buroker TR; O'Connell MJ; Wieand HS; Krook JE; Gerstner JB; Mailliard JA; Schaefer PL; Levitt R; Kardinal CG; Gesme DH
    J Clin Oncol; 1994 Jan; 12(1):14-20. PubMed ID: 7677801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.